ArticleCost effectiveness and resource allocation : C/E2022

Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system.

Kengo Harigane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.